Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

Back to Search
Print
Bookmark Trial

NCT00796510

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Fountain Valley, California, 92708, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Previously enrolled in B1321001 for at least 4 weeks.

- Previously enrolled in B1321003, discontinued from the study.

- Completed the B1321003 study as planned.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Treated with an investigational drug (other than sitaxsentan or sildenafil in either
B1321001 or B1321003) or device that has not received regulatory approval within the
30 days prior to Baseline/Day 1 or during the study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pulmonary Arterial Hypertension, Pulmonary HypertensionSafety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
NCT01642407
  1. Sagamihara, Kanagawa
  2. Suita, Osaka
  3. Ota-ku, Tokyo
  4. Setagaya-ku, Tokyo
  5. Shizuoka,
ALL GENDERS
1 Year+
years
MULTIPLE SITES
Pulmonary Arterial Hypertension, Pulmonary HypertensionStudy Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
NCT00796510
  1. Fountain Valley, California
  2. Cluj Napoca,
  3. Kyiv,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Pulmonary Arterial Hypertension, Pulmonary HypertensionSitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
NCT00795639
  1. Fountain Valley, California
  2. Mather, California
  3. Sacramento, California
  4. Englewood, Colorado
  5. Littleton, Colorado
  6. Gainesville, Florida
  7. Sarasota, Florida
  8. Weston, Florida
  9. Chicago, Illinois
  10. Olathe, Kansas
  11. Towson, Maryland
  12. Boston, Massachusetts
  13. Omaha, Nebraska
  14. New Brunswick, New Jersey
  15. Islandia, New York
  16. Stony Brook, New York
  17. Chapel Hill, North Carolina
  18. Cincinnati, Ohio
  19. Cleveland, Ohio
  20. Lancaster, Pennsylvania
  21. Lancaster, Pennsylvania
  22. Philadelphia, Pennsylvania
  23. Pittsburgh, Pennsylvania
  24. Providence, Rhode Island
  25. Charleston, South Carolina
  26. Dallas, Texas
  27. Houston, Texas
  28. San Antonio, Texas
  29. Temple, Texas
  30. Lynchburg, Virginia
  31. Richmond, Virginia
  32. Milwaukee, Wisconsin
  33. Buenos Aires,
  34. Buenos Aires,
  35. Buenos Aires,
  36. Buenos Aires,
  37. Sofia,
  38. Sofia,
  39. Veliko Turnovo,
  40. Temuco,
  41. Changsha, Hunan
  42. Xi'an, Shanxi
  43. Beijing,
  44. Shanghai,
  45. Shanghai,
  46. Bogotá, Cundinamarca
  47. Escazu, San Jose
  48. Praha 2,
  49. Santo Domingo, República Dominicana
  50. Santo Domingo,
  51. Guatemala,
  52. Hyderabad, Andhera Pradesh
  53. Hyderabad, Andhra Pradesh
  54. Ahmedabad, Gujarat
  55. Surat, Gujarat
  56. Vadodara, Gujarat
  57. Pune, Maharashtra
  58. Coimbatore, Tamil Nadu
  59. Madurai, Tamil Nadu
  60. Georgetown, Penang
  61. Mexico, DF
  62. Mexico, DF
  63. Monterrey, Nuevo Leon
  64. Lima,
  65. Lima,
  66. Quezon City,
  67. Cluj Napoca,
  68. Iasi,
  69. Moscow,
  70. Moscow,
  71. Saint-Petersburg,
  72. Saint-Petersburg,
  73. Saint-Petersburg,
  74. Riyadh,
  75. Belgrade,
  76. Bratislava,
  77. Cape Town, Western Cape
  78. Cape Town,
  79. Johannesburg,
  80. Stellenbosch,
  81. Bangkoknoi, Bangkok
  82. Bangkok,
  83. Istanbul, Fatih,
  84. Kyiv,
  85. Kyiv,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Pulmonary Arterial Hypertension, Pulmonary HypertensionStudy Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
NCT00796666
  1. Fountain Valley, California
  2. Gainesville, Florida
  3. Weston, Florida
  4. Boston, Massachusetts
  5. Omaha, Nebraska
  6. Chapel Hill, North Carolina
  7. Cincinnati, Ohio
  8. Cleveland, Ohio
  9. Providence, Rhode Island
  10. Houston, Texas
  11. San Antonio, Texas
  12. Milwaukee, Wisconsin
  13. Buenos Aires,
  14. Buenos Aires,
  15. Buenos Aires,
  16. Buenos Aires,
  17. Sofia,
  18. Temuco,
  19. Changsha, Hunan
  20. Beijing,
  21. Shanghai,
  22. Shanghai,
  23. Bogotá, Cundinamarca
  24. Praha 2,
  25. Hyderabad, Andhra Pradesh
  26. Hyderabad, Andhra Pradesh
  27. Ahmedabad, Gujarat
  28. Ahmedabad, Gujarat
  29. Surat, Gujarat
  30. Vadodara, Gujarat
  31. Pune, Maharashtra
  32. Coimbatore, Tamil Nadu
  33. Madurai, Tamil Nadu
  34. Georgetown, Penang
  35. Monterrey, Nuevo Leon
  36. Lima,
  37. Cluj Napoca,
  38. Iasi,
  39. Moscow,
  40. Moscow,
  41. Saint-Petersburg,
  42. Saint-Petersburg,
  43. Belgrade,
  44. Johannesburg,
  45. Bangkoknoi, Bangkok
  46. Istanbul, Fatih,
  47. Kyiv,
  48. Kyiv,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
Official Title  ICMJE A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension
Brief Summary As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH) therapy is these two oral drugs administered in combination.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Pulmonary Arterial Hypertension
  • Pulmonary Hypertension
Intervention  ICMJE
  • Drug: Sitaxsentan
    Sitaxsentan = 100 mg tablet administered orally, once daily
  • Drug: Sitaxsentan and Sildenafil
    Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
Study Arms  ICMJE
  • Experimental: Sitaxsentan
    Monotherapy arm
    Intervention: Drug: Sitaxsentan
  • Experimental: Sitaxsentan and Sildenafil
    Combination treatment
    Intervention: Drug: Sitaxsentan and Sildenafil
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: March 14, 2011)		3
Original Estimated Enrollment  ICMJE
 (submitted: November 20, 2008)		180
Actual Study Completion Date  ICMJE January 2011
Actual Primary Completion Date January 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Previously enrolled in B1321001 for at least 4 weeks.
  • Previously enrolled in B1321003, discontinued from the study.
  • Completed the B1321003 study as planned.

Exclusion Criteria:

  • Treated with an investigational drug (other than sitaxsentan or sildenafil in either B1321001 or B1321003) or device that has not received regulatory approval within the 30 days prior to Baseline/Day 1 or during the study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 16 Years to 80 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Romania,   Ukraine,   United States
Removed Location Countries Argentina,   Bulgaria,   Chile,   China,   Colombia,   Costa Rica,   Czech Republic,   Dominican Republic,   India,   Mexico,   Peru,   Philippines,   Russian Federation,   Saudi Arabia,   Serbia,   Slovakia,   South Africa,   Thailand
 
Administrative Information
NCT Number  ICMJE NCT00796510
Other Study ID Numbers  ICMJE B1321002
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP